Sales of Sovaldi, New Gilead Hepatitis C Drug, Soar to $10.3 Billion by ANDREW POLLACK

By ANDREW POLLACK

Global sales of the drug, in its first year on the market, fell short of those of AbbVie’s Humira, but Sovaldi outsold Humira in the United States.

Published: February 4, 2015 at 12:00AM

from NYT Business Day http://ift.tt/1Dbh8XU

from WordPress http://ift.tt/1xalQ0S

via Hadi Aboukhater